Biotechnology News

Scribe Therapeutics to participate in upcoming investor conferences

EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary...

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies...

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that...

Applied Biologics activates first Phase 3 BIOxHEAL™ clinical site — patient enrollment expected to begin shortly.

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...

MANCHESTER, United Kingdom, Sept. 01, 2026 (GLOBE NEWSWIRE) -- F2G Ltd., today announced abstracts accepted for presentation at the MSGERC 2026 Biennial Meeting in September and ISPOR Europe 2026 in...

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years,...

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine...